FibroBiologics, Inc. Financing Cash Flow
FibroBiologics, Inc. (FBLG) reported Financing Cash Flow of $6.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-31
- FibroBiologics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $5.32M, a 21.69% increase year-over-year.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $952.00K.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $3.19M, a 65.81% decline year-over-year.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $7.57M, a 55.26% decline from fiscal 2024.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $16.91M, a 22.58% increase from fiscal 2023.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $13.79M, a 132.79% increase from fiscal 2022.
- FibroBiologics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $5.92M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $6.28M 10-Q · filed 2026-07-31 | $9.47M derived: sum of 3 quarters · filed 2026-07-31 | $9.47M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $952.00K 10-Q · filed 2026-04-30 | $4.14M derived: sum of 2 quarters · filed 2026-04-30 | $4.14M derived: sum of 3 quarters · filed 2026-04-30 | $8.52M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.19M derived: sum of 2 quarters · filed 2026-02-24 | $7.57M derived: sum of 3 quarters · filed 2026-07-31 | $7.57M 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $4.38M derived: sum of 2 quarters · filed 2026-07-31 | $4.38M 10-Q · filed 2025-10-31 | $13.71M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $4.38M 10-Q · filed 2026-07-31 | $13.71M derived: sum of 3 quarters · filed 2026-07-31 | $18.18M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $9.33M derived: sum of 2 quarters · filed 2026-04-30 | $13.80M derived: sum of 3 quarters · filed 2026-04-30 | $13.63M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $13.80M derived: sum of 2 quarters · filed 2026-02-24 | $13.63M derived: sum of 3 quarters · filed 2026-02-24 | $16.91M 10-K · filed 2026-02-24 |
| 2024-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-31 | $4.30M derived: sum of 2 quarters · filed 2025-10-31 | $7.58M 10-Q · filed 2025-10-31 | $7.58M derived: sum of 4 quarters · filed 2025-10-31 |
| 2024-06-30 | -$172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.11M 10-Q · filed 2025-07-31 | $3.11M derived: sum of 3 quarters · filed 2025-07-31 | $4.05M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $3.28M 10-Q · filed 2025-05-14 | $3.28M derived: sum of 2 quarters · filed 2025-05-14 | $4.22M derived: sum of 3 quarters · filed 2025-05-14 | $2.50M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $940.00K derived: sum of 2 quarters · filed 2025-03-31 | -$773.00K derived: sum of 3 quarters · filed 2025-03-31 | $13.79M 10-K · filed 2025-03-31 |
| 2023-09-30 | $940.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$773.00K derived: sum of 2 quarters · filed 2024-11-12 | $13.79M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $12.85M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $14.57M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $5.92M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |